-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, one year after restarting the clinical practice, Amgen announced that it would abandon the development of its only BCMA drug, AMG701, for the reason given "for corporate strategic considerations"
The editor summarizes the development of BCMA/CD3 double antibody.
The editor summarizes the development of BCMA/CD3 double antibody.
1.
2.
3.